These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 17434275)

  • 41. Drugs in oral fluid Part II. Investigation of drugs in drivers.
    Wylie FM; Torrance H; Seymour A; Buttress S; Oliver JS
    Forensic Sci Int; 2005 Jun; 150(2-3):199-204. PubMed ID: 15944060
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of Drugs in Oral Fluid Samples Using a Commercially Available Collection Device: Agreement with Urine Testing and Evaluation of A and B Samples Obtained from Employees at Different Workplace Settings with Uncontrolled Sampling Procedures.
    Zheng Y; Sparve E; Sparring S; Bergström M
    J Anal Toxicol; 2021 Jan; 44(9):1004-1011. PubMed ID: 32128555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stability of drugs of abuse in oral fluid collection devices with purpose of external quality assessment schemes.
    Ventura M; Pichini S; Ventura R; Leal S; Zuccaro P; Pacifici R; de la Torre R
    Ther Drug Monit; 2009 Apr; 31(2):277-80. PubMed ID: 19307939
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of a rapid bedside toxicology screen in patients suspected of drug toxicity.
    Tomaszewski C; Runge J; Gibbs M; Colucciello S; Price M
    J Emerg Med; 2005 May; 28(4):389-94. PubMed ID: 15837018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of physicians as medical review officers in workplace drug testing programs. In pursuit of the last nanogram.
    Clark HW
    West J Med; 1990 May; 152(5):514-24. PubMed ID: 2190419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An evaluation of selected oral fluid point-of-collection drug-testing devices.
    Crouch DJ; Walsh JM; Flegel R; Cangianelli L; Baudys J; Atkins R
    J Anal Toxicol; 2005; 29(4):244-8. PubMed ID: 15975256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of a training program for device operators in the Australian Government's Point of Care Testing in General Practice Trial: issues and implications for rural and remote practices.
    Shephard MD; Mazzachi BC; Watkinson L; Shephard AK; Laurence C; Gialamas A; Bubner T
    Rural Remote Health; 2009; 9(3):1189. PubMed ID: 19689171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Administrative issues related to addiction in the workplace.
    Roberts S; Fallon LF
    Occup Med; 2001; 16(3):509-15, v. PubMed ID: 11401795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recommendations for toxicological investigation of drug impaired driving.
    Farrell LJ; Kerrigan S; Logan BK
    J Forensic Sci; 2007 Sep; 52(5):1214-8. PubMed ID: 17680796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Drug analytics in oral fluid using immunoassay].
    Dierich O; Soyka M
    Fortschr Neurol Psychiatr; 2005 Jul; 73(7):401-8. PubMed ID: 16012919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drugs in oral fluid in randomly selected drivers.
    Drummer OH; Gerostamoulos D; Chu M; Swann P; Boorman M; Cairns I
    Forensic Sci Int; 2007 Aug; 170(2-3):105-10. PubMed ID: 17658711
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of ten oral fluid point-of-collection drug-testing devices.
    Walsh JM; Crouch DJ; Danaceau JP; Cangianelli L; Liddicoat L; Adkins R
    J Anal Toxicol; 2007; 31(1):44-54. PubMed ID: 17389083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. There are disadvantages, too, for oral fluid, on-site urine testing.
    Silvaggio T; Prezzia CP
    Occup Health Saf; 2001 Dec; 70(12):8. PubMed ID: 11799564
    [No Abstract]   [Full Text] [Related]  

  • 54. Oral fluid testing for drugs of abuse.
    Bosker WM; Huestis MA
    Clin Chem; 2009 Nov; 55(11):1910-31. PubMed ID: 19745062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Workplace drug testing and worker drug use.
    Carpenter CS
    Health Serv Res; 2007 Apr; 42(2):795-810. PubMed ID: 17362218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug testing in the workplace: integrating medical review officer duties into occupational medicine.
    Smith DE; Glatt W; Tucker DE; Deutsch R; Seymour RB
    Occup Med; 2002; 17(1):79-90, v. PubMed ID: 11726338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug testing as part of the war on drugs.
    Gerson B; Subramaniam S
    Clin Lab Med; 1998 Dec; 18(4):781-803, xi. PubMed ID: 9891615
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A protocol to evaluate drug-related workplace impairment.
    Reisfield GM; Shults T; Demery J; Dupont R
    J Pain Palliat Care Pharmacother; 2013 Mar; 27(1):43-8. PubMed ID: 23527668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The medical review officer: a potential role for the medical examiner.
    Sgan SL; Hanzlick R
    Am J Forensic Med Pathol; 2003 Dec; 24(4):346-50. PubMed ID: 14634473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A snapshot of workplace drug testing in the UK.
    George S
    Occup Med (Lond); 2005 Jan; 55(1):69-71. PubMed ID: 15699095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.